An innovative protocol, cyclic hormone-chemotherapy in the treatment of high-risk localized endometrial cancer
Audet-Lapointe, P.; Ayoub, J.; Methot, Y.
Journal de Gynecologie Obstetrique et Biologie de la Reproduction 17(6): 751-755
1988
ISSN/ISBN: 0368-2315 PMID: 3209835 Document Number: 325164
Document emailed within 1 workday
Related Documents
Wen, H.-w.; Tian, F.; Ma, L.; Liao, Q.-p. 2009: Effects of postoperative chemotherapy on the prognosis of patients with high-risk early stage endometrial cancer Zhonghua Fu Chan Ke Za Zhi 44(3): 196-199Mangili, G.; De Marzi, P.; Viganò, R.; Rabaiotti, E.; Sassi, I.; Taccagni, G.L.; Garancini, P.; Frigerio, L. 2002: Identification of high risk patients with endometrial carcinoma. Prognostic assessment of endometrial cancer European Journal of Gynaecological Oncology 23(3): 216-220
Cinek, P.; Filip, S.; Vanasek, J.; Mericka, P.; Blaha, M.; Zouhar, M. 2007: Intensive cyclic chemotherapy and transplantation of autologous peripheral blood progenitor cells (PBPC) or whole blood in high-risk breast cancer - follow up at 10 years Experimental Oncology 29(2): 144-151
Altundag, K. 2018: Concurrent administration of aromatase inhibitors with chemotherapy might show better outcome in high risk hormone-receptor positive early-stage breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1559-1560
Tavani, A.; La Vecchia, C.; Brinton, L.A.; McTiernan, A. 2001: Hormone replacement therapy and risk of endometrial cancer Tumori 87(5): S20-S21
Cook, L.S.; Dong, Y.; Round, P.; Huang, X.; Magliocco, A.M.; Friedenreich, C.M. 2014: Hormone contraception before the first birth and endometrial cancer risk Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 23(2): 356-361
Bourlon, M.ía.T.; Mora, M.; Hinojosa-Fano, J.; Martínez-Benitez, B.; Amini, A.; Castillejos-Molina, R.; Glodé, L.M. 2016: Man with Locally Advanced, High-Risk Prostate Cancer Asks about Adding Chemotherapy to his Treatment Oncology 30(1): 94-98
Magnusson, C.; Weiderpass, E. 2001: Hormone therapy in climacteric. Different effects of estrogen and gestagen on the risk of breast and endometrial cancer Lakartidningen 98(5): 418-421
1987: Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development JAMA 257(6): 796-800
Ohnoshi, T.; Hayashi, K.; Mizuta, J.; Tagawa, S.; Matsutomo, S.; Saito, S.; Kawashima, K.; Akagi, T.; Kimura, I. 1993: Brief induction chemotherapy followed by involved-field irradiation for the treatment of localized intermediate- and high-grade non-Hodgkin's lymphoma International Journal of Hematology 57(1): 61-66
Razis, E.D.; Samonis, G.; Cook, P.; Beer, M.; Mittelman, A.; Lake, D.E.; Feldman, E.J.; Puccio, C.; Ahmed, T. 1994: TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer Journal of Medicine 25(3-4): 241-250
Tsukamoto, T.; Fukui, I.; Kihara, K.; Goto, S.; Kitahara, S.; Kobayashi, T.; Kojima, S.; Oshima, H. 1996: Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy Hinyokika Kiyo. Acta Urologica Japonica 42(5): 351-356
Bearman, S.I.; Shpall, E.J.; Jones, R.B.; Cagnoni, P.J.; Ross, M. 1996: High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer Seminars in Oncology 23(1 Suppl 2: 60-67
Pannuti, F.; Di Marco, A.R.; Rossi, A.P.; Rocchetta, G.; Rubino, I.; Giovannini, M.; Fruet, F. 1981: Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary results Panminerva Medica 23(2): 93-96
Abu Hmeidan, F.; Bilek, K.; Baier, D.; Nuwayhid, M.; Kade, R. 1992: Ultrasound assessment of the endometrium in early detection of endometrial cancer in high risk patients Zentralblatt für Gynakologie 114(9): 455-458
Felix, A.S.; Gaudet, M.M.; La Vecchia, C.; Nagle, C.M.; Shu, X.O.; Weiderpass, E.; Adami, H.O.; Beresford, S.; Bernstein, L.; Chen, C.; Cook, L.S.; De Vivo, I.; Doherty, J.A.; Friedenreich, C.M.; Gapstur, S.M.; Hill, D.; Horn-Ross, P.L.; Lacey, J.V.; Levi, F.; Liang, X.; Lu, L.; Magliocco, A.; McCann, S.E.; Negri, E.; Olson, S.H.; Palmer, J.R.; Patel, A.V.; Petruzella, S.; Prescott, J.; Risch, H.A.; Rosenberg, L.; Sherman, M.E.; Spurdle, A.B.; Webb, P.M.; Wise, L.A.; Xiang, Y.-B.; Xu, W.; Yang, H.P.; Yu, H.; Zeleniuch-Jacquotte, A.; Brinton, L.A. 2015: Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium International Journal of Cancer 136(5): E410-E422
Burnett, O.Lee.; De lo Santos, J.F. 2013: Multimodality therapy for high-risk endometrial cancer: balancing the courses while keeping all options on the table Oncology 27(10): 1001 1006 1011
Klaritsch, P.; Reich, O.; Regauer, S.; Bauernhofer, T. 2006: Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem-cell support: A case report European Journal of Gynaecological Oncology 27(3): 297-298
Evans, R.A. 1998: Radiotherapy and chemotherapy in high-risk breast cancer New England Journal of Medicine 338(5): 331; Author Reply 331-332
Fujinaka, R.; Otowa, Y.; Yokoo, H.; Arai, K.; Murata, K.; Mii, Y.; Kakinoki, K.; Oka, S.; Kuroda, D. 2019: Adjuvant Chemotherapy for High-Risk Stage Ⅱ Colon Cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(8): 1327-1329